Favourable Prognosis of Patients With Untreated HBeAg ‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU / mL
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.18383 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Jian Wang und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B e Antigens, Hepatitis B Surface Antigens, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Key Project supported by Medical Science and technology development Foundation, Nanjing Department of Health, Natural Science Foundation of Jiangsu Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Serum hepatitis B surface antigen (HBsAg) < 100 IU/mL has been recently proposed as one of the key criteria of ‘partial cure’ in patients with chronic hepatitis B virus (HBV) infection. We analysed the clinical prognosis of hepatitis B e antigen (HBeAg)‐negative untreated patients with HBsAg < 100 IU/mL and normal alanine aminotransferase (ALT) levels.
Methods
Five hundred and twenty‐one untreated patients with HBeAg negativity, HBsAg < 100 IU/mL and normal ALT levels were included from three hospitals. Spontaneous HBsAg seroclearance, phase transition, liver fibrosis progression and hepatocellular carcinoma (HCC) development were analysed.
Results
The median age was 43.0 years, and 62.2% of the patients were male. After a median follow‐up of 25.0 months, 52 (10.0%) patients achieved spontaneous HBsAg seroclearance. The annual HBsAg seroclearance rate is 4.2%. Patients with baseline HBsAg ≤ 10 IU/mL (adjusted hazard ratio [aHR] = 3.490, p < 0.001) and male sex (aHR = 1.980, p = 0.041) were more likely to achieve HBsAg seroclearance. Only 4 (0.8%) and 23 (4.8%) patients transitioned to the immune escape phase and HBeAg‐negative indeterminate phase, respectively. Baseline serum HBsAg > 10 IU/mL (aHR = 3.846, p = 0.034) and detectable HBV DNA (aHR = 2.672, p = 0.023) were associated with transition to the HBeAg‐negative indeterminate phase. No patient developed HCC or had fatal outcomes.
Conclusions
HBeAg‐negative patients with serum HBsAg < 100 IU/mL and normal ALT levels had a favourable prognosis. HBsAg ≤ 10 IU/mL and male sex were associated with a higher rate of HBsAg seroclearance, while HBsAg > 10 IU/mL and detectable HBV DNA were associated with a higher risk of transition to the indeterminate phase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, Jiangsu, China.
- Institute of Viruses and Infectious Diseases, Nanjing University, Nanjing, Jiangsu, China.
- Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Infectious Diseases, The Affiliated Infectious Diseases Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Jiangsu University, Nanjing, Jiangsu, China.
Förderung
- Key Project supported by Medical Science and technology development Foundation, Nanjing Department of Health
- Natural Science Foundation of Jiangsu Province
- National Natural Science Foundation of China
- Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
- Nanjing Medical Science and Technique Development Foundation
Zitieren
APA
Wang, J., Zhang, Z., Yin, S., Zhang, S., Zhu, L., Pan, Y., Fan, T., Cao, F., Xiong, Y., Jiang, C., Wang, G., Yang, Y., Jia, B., Liu, J., Xia, J., Yan, X., Li, J., Zhu, C., Liu, X., …, & Huang, R. (2025). Favourable Prognosis of Patients With Untreated HBeAg ‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU / mL. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18383
Vancouver
Wang J, Zhang Z, Yin S, Zhang S, Zhu L, Pan Y, et al. Favourable Prognosis of Patients With Untreated HBeAg ‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU / mL. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.18383
BibTeX
@article{Wang2025,
author = {Wang, Jian and Zhang, Zhiyi and Yin, Shengxia and Zhang, Shaoqiu and Zhu, Li and Pan, Yifan and Fan, Tao and Cao, Fei and Xiong, Ye and Jiang, Chao and Wang, Guiyang and Yang, Yue and Jia, Bei and Liu, Jiacheng and Xia, Juan and Yan, Xiaomin and Li, Jie and Zhu, Chuanwu and Liu, Xingxiang and Chen, Yuxin and Wu, Chao and Huang, Rui},
title = {Favourable Prognosis of Patients With Untreated HBeAg ‐Negative Chronic Hepatitis B Virus Infection With HBsAg < 100 IU / mL},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.18383}
}
EUVIMED